9.42
Schlusskurs vom Vortag:
$9.11
Offen:
$9.38
24-Stunden-Volumen:
5.02M
Relative Volume:
1.39
Marktkapitalisierung:
$1.17B
Einnahmen:
$631.73M
Nettoeinkommen (Verlust:
$-239.78M
KGV:
-4.6634
EPS:
-2.02
Netto-Cashflow:
$-33.45M
1W Leistung:
-1.15%
1M Leistung:
+16.30%
6M Leistung:
-40.64%
1J Leistung:
-58.19%
10 X Genomics Inc Stock (TXG) Company Profile
Firmenname
10 X Genomics Inc
Sektor
Branche
Telefon
(925) 401-7300
Adresse
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Vergleichen Sie TXG mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
TXG
10 X Genomics Inc
|
9.42 | 1.17B | 631.73M | -239.78M | -33.45M | -2.02 |
![]()
VEEV
Veeva Systems Inc
|
285.36 | 45.71B | 2.86B | 780.66M | 1.20B | 4.72 |
![]()
TEM
Tempus Ai Inc
|
62.07 | 9.42B | 803.32M | -709.10M | -212.68M | -7.8003 |
![]()
DOCS
Doximity Inc
|
58.85 | 9.78B | 550.17M | 201.35M | 232.07M | 1.00 |
![]()
HQY
Healthequity Inc
|
111.55 | 8.70B | 1.15B | 96.70M | -161.99M | 1.09 |
![]()
WAY
Waystar Holding Corp
|
41.16 | 6.92B | 906.14M | -52.62M | 89.62M | -0.3621 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-02-13 | Herabstufung | Leerink Partners | Outperform → Market Perform |
2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
2024-07-22 | Hochstufung | Jefferies | Hold → Buy |
2024-07-18 | Herabstufung | JP Morgan | Overweight → Neutral |
2024-07-10 | Herabstufung | Deutsche Bank | Buy → Hold |
2024-06-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
2024-06-25 | Herabstufung | Guggenheim | Buy → Neutral |
2024-06-03 | Fortgesetzt | Jefferies | Hold |
2024-05-01 | Herabstufung | TD Cowen | Buy → Hold |
2023-12-14 | Eingeleitet | Guggenheim | Buy |
2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
2023-12-12 | Hochstufung | BofA Securities | Underperform → Neutral |
2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
2023-05-10 | Eingeleitet | Barclays | Overweight |
2023-03-31 | Eingeleitet | Stephens | Overweight |
2023-02-02 | Eingeleitet | UBS | Neutral |
2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
2022-08-18 | Herabstufung | Goldman | Neutral → Sell |
2022-07-25 | Eingeleitet | Canaccord Genuity | Buy |
2022-07-15 | Herabstufung | BofA Securities | Neutral → Underperform |
2022-07-15 | Herabstufung | William Blair | Outperform → Mkt Perform |
2021-10-15 | Fortgesetzt | Cowen | Outperform |
2021-09-14 | Herabstufung | BofA Securities | Buy → Neutral |
2021-03-15 | Eingeleitet | William Blair | Outperform |
2020-12-02 | Eingeleitet | Goldman | Neutral |
2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
2020-07-10 | Eingeleitet | Stifel | Buy |
2020-03-05 | Eingeleitet | Guggenheim | Buy |
2020-01-07 | Eingeleitet | Citigroup | Buy |
2019-10-07 | Eingeleitet | BofA/Merrill | Buy |
2019-10-07 | Eingeleitet | Cowen | Outperform |
2019-10-07 | Eingeleitet | JP Morgan | Overweight |
2019-09-24 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
10 X Genomics Inc Aktie (TXG) Neueste Nachrichten
Forecasting The Future: 7 Analyst Projections For 10x Genomics - Benzinga
Long Read Sequencing Market Key Players Analysis10X Genomics, - openPR.com
10x Genomics, Inc. (NASDAQ:TXG) Stock Holdings Increased by Deutsche Bank AG - Defense World
ARK Investment Acquires 290K Shares of 10x Genomics (TXG) | TXG Stock News - GuruFocus
10x Genomics, Inc. (TXG) Stock Analysis: Evaluating the 31.90% Potential Upside - DirectorsTalk Interviews
Cathie Wood's ARK Investment Acquires Significant Stake in 10x G - GuruFocus
Layoff Tracker: Keros Cuts 45% of Workforce Along With Pulmonary Hypertension Drug - BioSpace
10 Best Healthcare Stocks to Invest In (June 2025) - Securities.io
ARK Investment Acquires 342K Shares of 10x Genomics (TXG) | TXG Stock News - GuruFocus
Cetera Investment Advisers Raises Stake in 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
Cathie Wood’s ARK buys Intellia, 10x Genomics, sells Tesla stock By Investing.com - Investing.com Nigeria
Cathie Wood’s ARK buys Intellia, 10x Genomics, sells Tesla stock - Investing.com
10x Genomics, Inc. (NASDAQ:TXG) Given Average Recommendation of “Hold” by Analysts - Defense World
Powell, Mayville Engineering, Graham Corporation, Hyster-Yale Materials Handling, and 10x Genomics Shares Skyrocket, What You Need To Know - Yahoo Finance
Shareholders May Be Wary Of Increasing 10x Genomics, Inc.'s (NASDAQ:TXG) CEO Compensation Package - simplywall.st
10x Genomics, Inc. (TXG) Stock Analysis: A 52.56% Potential Upside Amidst a Challenging Market - DirectorsTalk Interviews
10x Genomics’ (TXG) “Sell (E+)” Rating Reiterated at Weiss Ratings - Defense World
10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Bank of America Corp DE - Defense World
Why 10x Genomics Stock Was Sliding This Week - Barchart.com
10x Genomics Reports Third Quarter 2023 Financial Results - Seeking Alpha
10x Genomics Reports First Quarter 2024 Financial Results - Seeking Alpha
Gotham Asset Management LLC Takes $264,000 Position in 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
10x Genomics (TXG) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
10x Genomics (NASDAQ:TXG) Price Target Lowered to $18.00 at Morgan Stanley - Defense World
10x Genomics (NASDAQ:TXG) Shares Down 4.8% Following Analyst Downgrade - Defense World
High-Throughput Transcriptomics 2025–2028: Next-Gen Breakthroughs Set to Disrupt Genomics Market - macnifico.pt
10x Genomics (TXG) Price Target Lowered by Morgan Stanley | TXG Stock News - GuruFocus
10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Northern Trust Corp - Defense World
Stephens Reaffirms Overweight Rating for 10x Genomics (NASDAQ:TXG) - Defense World
'Shooting ourselves in the foot': Trump administration cuts force East Bay’s 10x Genomics into layoffs - The Business Journals
Dimensional Fund Advisors LP Sells 23,956 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
NanoString to pay 10x Genomics $68m in global settlement - Life Sciences Intellectual Property Review
10x Genomics reaches settlement with Bruker - Medical Buyer
Stifel Financial Corp Raises Holdings in 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
UBS Group Lowers 10x Genomics (NASDAQ:TXG) Price Target to $12.00 - Defense World
10x Genomics Reaches $68 Million Patent Settlement With Bruker - marketscreener.com
10x Genomics Settles Litigation with Bruker Corporation - TipRanks
10x Genomics settles patent dispute with Bruker for $68 million - Investing.com
10x Genomics Announces Patent Litigation Settlement Agreement with Bruker - Financial Times
All Ongoing Lawsuits Between Bruker And 10X Genomics To Be Withdrawn - marketscreener.com
Earnings Release: Here's Why Analysts Cut Their 10x Genomics, Inc. (NASDAQ:TXG) Price Target To US$12.96 - simplywall.st
10x Genomics (TXG) Price Target Reduced by UBS Amid Funding Chal - GuruFocus
Bruker and 10x Genomics settle patent dispute - Yahoo Finance
10x Genomics, Bruker Strike Deal After $31M Patent Verdict - Law360
10x Genomics (TXG) Sees Price Target Lowered by UBS | TXG Stock News - GuruFocus
UPC battle between 10x Genomics and Curio Bioscience moves to next stage - JUVE Patent
UBS Adjusts Price Target on 10x Genomics to $12 From $14, Maintains Neutral Rating - marketscreener.com
Canaccord Adjusts 10x Genomics (TXG) Price Target Citing Market Uncertainty | TXG Stock News - GuruFocus
10x Genomics (TXG) Price Target Reduced by UBS Amid Funding Challenges | TXG Stock News - GuruFocus
10x Genomics (NASDAQ:TXG) Price Target Lowered to $6.50 at The Goldman Sachs Group - Defense World
10x Genomics (NASDAQ:TXG) Price Target Cut to $15.00 by Analysts at Canaccord Genuity Group - Defense World
Finanzdaten der 10 X Genomics Inc-Aktie (TXG)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):